Use of xenon as neuroprotectant in a neonatal subject
View Patent ↗The present invention relates to the use of xenon in the preparation of a medicament for preventing and/or alleviating one or more anesthetic-induced neurological deficits in a neonatal subject. The present invention further relates to combinations of xenon and sevoflurane, and use thereof as preconditioning agents for administration prior to hypoxic-ischaemic injury.
1. A method of reducing the severity of a neurological deficit, the method comprising administering a therapeutically effective amount of xenon and a GABAergic agent to a subject at risk of suffering the neurological deficit, wherein the xenon and the GABAergic agent are administered to the subject in a gas comprising from 10-20% xenon and 0.67%-4% GABAergic agent, wherein the reducing the severity comprises maintaining more viable neurons, relative to neurons in a control, after exposure to a stimulus that causes the neurological deficit.
2. The method of claim 1 , wherein the neurological deficit is associated with neuronal apoptosis, neuronal necrosis, or neuronal injury.
3. The method of claim 1 , wherein the GABAergic agent is isoflurane, sevoflurane or desflurane.
4. The method of claim 1 , wherein the GABAergic agent is isoflurane, and the neurological deficit is associated with hypoxia.
5. The method of claim 1 , wherein the GABAergic agent is sevoflurane, and the neurological deficit is associated with hypoxia.
6. The method of claim 1 , wherein the GABAergic agent is desflurane, and the neurological deficit is associated with hypoxia.
7. The method of claim 1 , wherein the control comprises a value obtained by measuring viability of neurons exposed to the stimulus of the neurological deficit but not exposed to the gas.
8. The method of claim 7 , wherein the stimulus of the neurological deficit comprises exposing the neurons to a hypoxic condition.